Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cinthya Coronado
Observed names:
C Coronado,
C. Coronado,
Coronado, C.
Institution:
Incyte (United States)
Observed institutions:
Hospital Universitario 12 De Octubre,
Institut Català d'Oncologia,
PharmaMar (Spain),
Royal Marsden Hospital,
Instituto Alexander Fleming,
Fundación para la Investigación, Docencia y Prevención del Cáncer,
University of Glasgow,
Incyte (United States)
show all 8
OpenAlex ID:
A5111838860
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
2013
·
R. Salazar
, H. Cortés-Funes
, et al.
·
Cancer Chemotherapy and Pharmacology
·
33
Nonscheduled consultation in oncologic patients. How many of them are true emergencies? An observational prospective study
2004
·
F. A. Díaz-Couselo
, J. M. O’Connor
, et al.
·
Supportive Care in Cancer
·
31
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
2018
·
Elena Elez
, Carlos Gomez-Roca
, et al.
·
Investigational New Drugs
·
22
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
2012
·
R. Salazar
, R. J. Jones
, et al.
·
Cancer Chemotherapy and Pharmacology
·
22
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
2012
·
T A Yap
, H Cortes-Funes
, et al.
·
British Journal of Cancer
·
21
PDF
Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive pts
2008
·
J. Sepulveda
, P. Maroto
, et al.
·
Journal of Clinical Oncology
·
19
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
2012
·
Christophe Massard
, Jane Margetts
, et al.
·
Investigational New Drugs
·
18
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
2015
·
Mark J. Ratain
, David Geary
, et al.
·
Investigational New Drugs
·
15
Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis
2011
·
Arturo Soto-Matos
, Sergio Szyldergemajn
, et al.
·
Marine Drugs
·
15
PDF
Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study
2022
·
Noriko Fukuhara
, Youko Suehiro
, et al.
·
Cancer Science
·
10
PDF
Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
2015
·
Sanjay Goel
, Santiago Viteri
, et al.
·
Investigational New Drugs
·
10
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies
2014
·
Francois Goldwasser
, Sandrine Faivre
, et al.
·
Investigational New Drugs
·
9
Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
2015
·
Enrique M. Ocio
, Albert Oriol
, et al.
·
British Journal of Haematology
·
8
PDF
A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
2013
·
J. Capdevila
, S. Clive
, et al.
·
Cancer Chemotherapy and Pharmacology
·
8
Elisidepsin
2010
·
Coronado, C.
, Galmarini, C.M.
, et al.
·
Drug News & Perspectives
·
8
Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen
2014
·
Daniel E. Castellano
, Joaquim Bellmunt
, et al.
·
Cancer Chemotherapy and Pharmacology
·
6
361 Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors
2015
·
M. Hidalgo
, V. Boni
, et al.
·
European Journal of Cancer
·
5
Complete and Sustained Objective Response per RECIST to Irvalec (PM02734) in Undifferentiated Large Cell Esophageal Adenocarcinoma: A Case Report and a Review of the Literature
2012
·
Ramón Salazar
, Carmen Cuadra
, et al.
·
Case Reports in Oncology
·
5
Phase II Optimization, Open-Label Clinical Trial of Zalypsis® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients
2012
·
Enrique M Ocio
, Javier De La Rubia
, et al.
·
Blood
·
4
Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors.
2012
·
Sanjay Goel
, Teresa Moran
, et al.
·
Journal of Clinical Oncology
·
3
Phase I study of elisidepsin (E) in combination with carboplatin (C) in patients (pts) with advanced solid tumors.
2011
·
S. J. Faivre
, S. Ropert
, et al.
·
Journal of Clinical Oncology
·
2
Sunitinib therapy for patients with advanced renal cell carcinoma (aRCC): Analysis for safety and activity on single institution experience—Prolonged overall survival
2008
·
D. E. Castellano
, J. Sepulveda
, et al.
·
Journal of Clinical Oncology
·
2
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors
2014
·
Ramón Salazar
, Antonio Calles
, et al.
·
Investigational New Drugs
·
1
Abstract 5587: Phase I study of PM00104 in combination with carboplatin in patients (pts) with advanced solid tumors
2012
·
Emiliano Calvo
, Marta Gil
, et al.
·
Cancer Research
·
1
ChemInform Abstract: Elisidepsin: Antineoplastic Agent
2011
·
C. Coronado
, C. M. Galmarini
, et al.
·
ChemInform
·
1
Show more works
View as search
Works count:
41
Citation count:
282
H-index:
10
I10-index:
11
Year
Topic
Type